10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed

FierceBiotechBial bails after Parkinson’s fail, axing asset over phase 2 miss

Clinical OMICsGenome Wide Analysis Broadens Genetic Knowledge of Anxiety

FierceBiotechGSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer

Roche MediaGSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer - Fierce Biotech

LabiotechPharma in Spain: why global investors and innovators are moving in

Endpoints NewsGSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B

eLifeExperience shapes the transformation of olfactory representations along the cortico-hippocampal pathway

10x Genomics Blog10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman - Stock Titan

10x Genomics Blog10x Genomics (TXG) awards 8,829 RSUs to board director - Stock Titan

10x Genomics News10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs - Stock Titan

10x Genomics News10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings - Stock Titan

10x Genomics News10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com